<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4763">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02517489</url>
  </required_header>
  <id_info>
    <org_study_id>PHRN14-PFD/CAPE COD</org_study_id>
    <nct_id>NCT02517489</nct_id>
  </id_info>
  <brief_title>Community-Acquired Pneumonia : Evaluation of Corticosteroids</brief_title>
  <acronym>CAPE_COD</acronym>
  <official_title>Effects of Low-dose Corticosteroids on Survival of Severe Community-acquired Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mortality of severe Community-Acquired Pneumonia (CAP) has not declined over time and is&#xD;
      between 25 and 30% in sub-groups of patients. Corticosteroids (CTx) could down-regulate&#xD;
      pulmonary and systemic inflammation, accelerate clinical resolution and decrease the rate of&#xD;
      inflammation-associated systemic complications. Two recent meta-analyses suggest a positive&#xD;
      effect on severe CAP day 28 survival when CTx are added to standard therapy. However they are&#xD;
      based on only four trials gathering less than 300 patients, of which only one was positive.&#xD;
      Recently published guidelines do not recommend CTx as part of CAP treatment. Therefore a&#xD;
      well-powered trial appears necessary to test the hypothesis that CTx - and more specifically&#xD;
      hydrocortisone - could improve day 28 survival of critically-ill patients with severe CAP,&#xD;
      severity being assessed either on a Pulmonary Severity Index â‰¥ 130 (Fine class V) or by the&#xD;
      use of mechanical ventilation or high-FiO2 high-flow oxygen therapy.&#xD;
&#xD;
      A phase-III multicenter add-on randomized controlled double-blind superiority trial assessing&#xD;
      the efficacy of hydrocortisone vs. placebo on Day 28 all-causes mortality, in addition to&#xD;
      antibiotics and supportive care, including the correction of hypoxemia.&#xD;
&#xD;
      Randomization will be stratified on: (i) centers; (ii) use of mechanical ventilation at the&#xD;
      time of inclusion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will receive state-of-the-art standard therapy for severe Community-Acquired&#xD;
      Pneumonia (CAP), including antibiotics and supportive care. Correction of hypoxemia will use&#xD;
      standard low-flow oxygen therapy, high-flow oxygen therapy, non-invasive-ventilation or&#xD;
      invasive ventilation with endotracheal tube, as required. Patients in the treatment group&#xD;
      will receive intra-venous hydrocortisone. Patients of the control group will receive an&#xD;
      intravenous placebo by intravenous route at the same frequency.&#xD;
&#xD;
      Hydrocortisone or placebo will be given in a double-blind fashion for 8 or 14 full days. The&#xD;
      intravenous route will be used. The treatment course will include 4 or 7 days of full dose&#xD;
      (200 mg/day by continuous infusion), 2 or 4 days of half dose (100 mg/day by continuous&#xD;
      infusion), and 2 or 3 days of tapering dose (50 mg/day by continuous infusion). Duration of&#xD;
      treatment is chosen upon patient initial improvement.&#xD;
&#xD;
      A substantial amendment to the CAPE COD study has been submitted to the Competent Authorities&#xD;
      in order to conduct a specific analysis on the sub-group of patients included with COVID19&#xD;
      (coronavirus disease 2019), in order to get a quick response in this specific population and&#xD;
      in the context of an epidemic emergency.&#xD;
&#xD;
      The aim is to answer as quickly as possible a therapeutic question of major importance in the&#xD;
      treatment of severe respiratory infections with CoV-2 SARS (severe acute respiratory syndrome&#xD;
      coronavirus 2). Modifications made to the original study for patients with COVID (coronavirus&#xD;
      disease) include some inclusion criteria, the primary endpoint, and secondary endpoints.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 28, 2015</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Day 28 all causes mortality</measure>
    <time_frame>at day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Day 21 failure</measure>
    <time_frame>at day 21</time_frame>
    <description>For the sub-group of patients included with COVID19, failure is defined as death or need of respiratory support (mechanical ventilation or high-flow oxygen therapy);</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>In patients non-invasively ventilated at inclusion, proportion of patients needing endotracheal intubation</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, for a maximum of 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In patients non-ventilated at inclusion, proportion of patients requiring non-invasive ventilation</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, for a maximum of 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In patients non-ventilated at inclusion, proportion of patients needing endotracheal intubation</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, for a maximum of 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day 28 ventilator-free-days</measure>
    <time_frame>between 0 and day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with vasopressor therapy initiation from inclusion to day 28</measure>
    <time_frame>between 0 and day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day 28 vasopressor-free-days</measure>
    <time_frame>between 0 and day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU and/or intermediate care unit LOS</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, for a maximum of 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-causes mortality at day 90</measure>
    <time_frame>at day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36 Health Survey at day 90</measure>
    <time_frame>at day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers: procalcitonin at baseline, day 3 and day 7</measure>
    <time_frame>at inclusion, day 3 and day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers: C-reactive protein at baseline, day 3 and day 7</measure>
    <time_frame>at inclusion, day 3 and day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers: plasmatic concentration of pro-inflammatory cytokines (IL-6, IL-20, IL-22, IL-22BP, HBD2, TNF) at baseline, day 3 and day 7</measure>
    <time_frame>at inclusion, day 3 and day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>P/F ratio measured daily from baseline to day 7, at the end of treatment, at the end of ICU-stay and/or day 28</measure>
    <time_frame>measured daily from baseline to day 7, at the end of treatment i.e 14 days after the start of treatment, at the end of ICU-stay (for a maximum of 28 days) and/or day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SOFA calculated daily from baseline to day 7, at the end of treatment, at the end of ICU-stay and/or day 28</measure>
    <time_frame>calculated daily from baseline to day 7, at the end of treatment (i.e 14 days after the start of treatment), at the end of ICU-stay (for a maximum of 28 days) and/or day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients experiencing secondary infection during their ICU-stay</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, for a maximum of 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients experiencing gastrointestinal bleeding during their ICU-stay</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, for a maximum of 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily amount of insulin administered to the patient from day 1 to day 7</measure>
    <time_frame>Patients will be followed from day 1 to day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight-gain at baseline and day 7</measure>
    <time_frame>Patients will be followed at baseline and day 7</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>P/F ratio measured daily from Day1 to Day7, at Day 14 and at Day 21 and/or at the end of ICU-stay</measure>
    <time_frame>from day 1 to day 7, at day 14 and day 21 and/or at the end of ICU-stay</time_frame>
    <description>Sub-group of patients included with COVID19</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of patients needing endotracheal intubation</measure>
    <time_frame>at day 21</time_frame>
    <description>Sub-group of patients included with COVID19</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of patients experiencing secondary infection during their ICU-stay</measure>
    <time_frame>From baseline to day 21</time_frame>
    <description>Sub-group of patients included with COVID19</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Community Acquired Pneumonia</condition>
  <arm_group>
    <arm_group_label>Hydrocortisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the treatment group will receive intra-venous hydrocortisone (in addition to the standard treatment of severe Community-Acquired Pneumonia (CAP)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients of the control group will receive an intravenous placebo by intravenous route (in addition to the standard treatment of severe Community-Acquired Pneumonia (CAP)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocortisone</intervention_name>
    <description>Hydrocortisone will be given in a double-blind fashion for 8 or 14 full days. The intravenous route will be used. The treatment course will include 4 or 7 days of full dose (200 mg/day by continuous infusion), 2 or 4 days of half dose (100 mg/day by continuous infusion), and 2 or 3 days of tapering dose (50 mg/day by continuous infusion). Duration of treatment is chosen upon patient initial improvement.</description>
    <arm_group_label>Hydrocortisone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be given in a double-blind fashion for 8 or 14 full days. The intravenous route will be used. The treatment course will include 4 or 7 days of full dose (200 mg/day by continuous infusion), 2 or 4 days of half dose (100 mg/day by continuous infusion), and 2 or 3 days of tapering dose (50 mg/day by continuous infusion). Duration of treatment is chosen upon patient initial improvement.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥ 18 years&#xD;
&#xD;
          -  Patients affiliated to social security scheme&#xD;
&#xD;
          -  Admission to an Intensive Care Unit (ICU) or intermediate care unit participating to&#xD;
             the trial&#xD;
&#xD;
          -  Diagnosis of Community- Acquired Pneumonia (CAP) suggested by at least two of the&#xD;
             following: cough, purulent sputum, chest pain and dyspnea&#xD;
&#xD;
          -  Focal shadowing/infiltrate on chest X-ray or CT-scan&#xD;
&#xD;
          -  Diagnosis of Community- Acquired Pneumonia (CAP) during the 48 hours post-hospital&#xD;
             admission&#xD;
&#xD;
          -  Study drug infusion initiated no longer than 24 hours post first severity criterion&#xD;
&#xD;
          -  Severity defined by at least one of the following:&#xD;
&#xD;
               -  Pneumonia Severity Index (PSI) &gt; 130 (Fine class V)&#xD;
&#xD;
               -  Patient placed on mechanical ventilation (invasive or not) for acute respiratory&#xD;
                  failure, with a PEEP level of 5 cm of water or more&#xD;
&#xD;
               -  Patient treated by high-flow oxygen therapy with a FiO2 of 50% or more and a P/F&#xD;
                  ratio less than 300&#xD;
&#xD;
               -  Patient treated by oxygen therapy with a partial rebreathing-mask with a&#xD;
                  reservoir bag, provided that the PaO2 is less than (cf. table):&#xD;
&#xD;
        Oxygen flow (L/min) 6 7 8 9 10 or more PaO2 (mmHg) less than 180 210 240 270 300&#xD;
&#xD;
          -  Patient already treated by antibiotics (at least one dose since admission to hospital)&#xD;
&#xD;
          -  Informed consent signed by the patient, its relatives or emergency procedure&#xD;
&#xD;
        On the sub-group of patients included with COVID19 :&#xD;
&#xD;
          -  Diagnosis of COVID19 either as certain (PCR) or probable (evocative clinical and&#xD;
             radiological features AND epidemic context AND absence of other microbiological&#xD;
             documentation).&#xD;
&#xD;
          -  Study drug infusion initiated no longer than 24 hours post first severity criterion ;&#xD;
             in case of transfer from another hospital, this period will be prolonged to 48 hours&#xD;
&#xD;
          -  Patient receiving the best available treatment as define by up-to-date scientific&#xD;
             knowledge&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient treated by vasopressors for septic shock at the time of inclusion&#xD;
&#xD;
          -  Clinical history suggesting of aspiration of gastric content&#xD;
&#xD;
          -  Patient treated by invasive mechanical ventilation within 14 days before current&#xD;
             hospital admission&#xD;
&#xD;
          -  Patient treated by antibiotics for a respiratory infection for more than seven days at&#xD;
             the admission to the hospital (except if a pathogen resistant to this antibiotics is&#xD;
             isolated)&#xD;
&#xD;
          -  History of cystic fibrosis&#xD;
&#xD;
          -  Post-obstructive pneumonia&#xD;
&#xD;
          -  Patients in which rapid PCR-test is positive for flu&#xD;
&#xD;
          -  Active tuberculosis or fungal infection&#xD;
&#xD;
          -  Active viral hepatitis or active infection with herpes viruses&#xD;
&#xD;
          -  Myelosuppression&#xD;
&#xD;
          -  Decision of withholding mechanical ventilation or endotracheal intubation&#xD;
&#xD;
          -  Hypersensitivity to corticosteroids&#xD;
&#xD;
          -  Patient needing anti-inflammatory corticosteroids or substitutive hydrocortisone for&#xD;
             any reason&#xD;
&#xD;
          -  Patients under treatment by more than 15 mg/d of prednisone (or equivalent) for more&#xD;
             than 30 days&#xD;
&#xD;
          -  Patient already enrolled in another drug trial with mortality as an end-point. If the&#xD;
             patient is already participating in another therapeutic trial with a different&#xD;
             endpoint, the investigator must verify that inclusion in CAPE COD can not prejudice&#xD;
             it.&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
&#xD;
          -  Patient on judicial protection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre-FranÃ§ois DEQUIN, MD-PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU de TOURS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pierre-FranÃ§ois DEQUIN, MD-PhD</last_name>
    <phone>02.47.47.38.55</phone>
    <phone_ext>+33</phone_ext>
    <email>pierre-franÃ§ois.dequin@univ-tours.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie LECLERC</last_name>
    <phone>02.47.47.46.64</phone>
    <phone_ext>+33</phone_ext>
    <email>m.leclerc@chu-tours.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service de RÃ©animation - UnitÃ© de Soins Continus, CH d'AngoulÃªme</name>
      <address>
        <city>'AngoulÃªme</city>
        <zip>16959</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe CRACCO, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christophe CRACCO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation Polyvalente, CH d'Argenteuil</name>
      <address>
        <city>Argenteuil</city>
        <zip>95107</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GaÃ«tan PLANTEFEVE, MD</last_name>
    </contact>
    <investigator>
      <last_name>GaÃ«tan PLANTEFEVE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation, CHR Metz-Thionville</name>
      <address>
        <city>Ars-Laquenexy</city>
        <zip>57530</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume LOUIS, MD</last_name>
    </contact>
    <investigator>
      <last_name>Guillaume LOUIS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation</name>
      <address>
        <city>Aulnay-sous-Bois</city>
        <zip>93602</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henri FAURE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Henri FAURE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation</name>
      <address>
        <city>Belfort</city>
        <zip>90015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julio BADIE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Julio BADIE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation</name>
      <address>
        <city>Bourg-en-Bresse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>RÃ©mi BRUYERE, MD</last_name>
    </contact>
    <investigator>
      <last_name>RÃ©mi BRUYERE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation HIA Clermont-Tonnerre</name>
      <address>
        <city>Brest</city>
        <zip>29240</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe GIACARDI, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christophe GIACARDI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation MÃ©dicale, CHU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erwann L'HER, MD-PhD</last_name>
    </contact>
    <investigator>
      <last_name>Erwann L'HER, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation, CHU CÃ´te de Nacre</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>AurÃ©lie JORET, MD</last_name>
    </contact>
    <investigator>
      <last_name>AurÃ©lie JORET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation MÃ©dicale, HÃ´pital Louis Pasteur, Chartres</name>
      <address>
        <city>Chartres</city>
        <zip>28000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation MÃ©dicale Polyvalente, HÃ´pital G Montpied</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bertrand SOUWEINE, MCU-PH</last_name>
    </contact>
    <investigator>
      <last_name>Bertrand SOUWEINE, MCU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation, HÃ´pital Louis Mourier</name>
      <address>
        <city>Colombes</city>
        <zip>92700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Damien RICARD, MCU-PH</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Damien RICARD, MCU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation MÃ©dicale, CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Pierre QUENOT, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Pierre QUENOT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation MÃ©dico-Chirurgicale, HÃ´pital Raymond PoincarrÃ©, APHP</name>
      <address>
        <city>Garches</city>
        <zip>92380</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Djillali ANNANE, MD-PhD</last_name>
    </contact>
    <investigator>
      <last_name>Djillali ANNANE, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation MÃ©dicale, CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas TERZI, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nicolas TERZI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation Polyvalente, CHD La Roche sur Yon</name>
      <address>
        <city>La Roche sur Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean REIGNIER, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jean REIGNIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation, CH Le Mans</name>
      <address>
        <city>Le Mans</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe GUITTON, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christophe GUITTON</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation Polyvalente, HÃ´pital Salengro, CHU de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MercÃ© JOURDAIN, MD-PhD</last_name>
    </contact>
    <investigator>
      <last_name>MercÃ© JOURDAIN, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation Polyvalente, CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno FranÃ§ois, MD</last_name>
    </contact>
    <investigator>
      <last_name>Bruno FranÃ§ois, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation MÃ©dicale, HÃ´pital Nord</name>
      <address>
        <city>Marseille</city>
        <zip>13015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent PAPAZIAN, MCU-PH</last_name>
    </contact>
    <investigator>
      <last_name>Laurent PAPAZIAN, MCU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation Polyvalente - Surveillance Continue, CH de Montauban</name>
      <address>
        <city>Montauban</city>
        <zip>82013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>FrÃ©dÃ©ric BELLEC, MD</last_name>
    </contact>
    <investigator>
      <last_name>FrÃ©dÃ©ric BELLEC, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation MÃ©dicale, CHU de Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SÃ©bastien GIBOT, MD-PhD</last_name>
    </contact>
    <investigator>
      <last_name>SÃ©bastien GIBOT, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation Polyvalente, HÃ´pital HÃ´tel Dieu, CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe GUITTON, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christophe GUITTON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation MÃ©dicale, CHR d'OrlÃ©ans</name>
      <address>
        <city>OrlÃ©ans</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry BOULAIN, MD</last_name>
    </contact>
    <investigator>
      <last_name>Thierry BOULAIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation MÃ©dicale, HÃ´pital Cochin, APHP</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Paul MIRA, MD-PhD</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Paul MIRA, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation et USC mÃ©dico-chirurgicale, HÃ´pital Tenon, APHP</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muriel-Sarah FARTOUKH, MD-PhD</last_name>
    </contact>
    <investigator>
      <last_name>Muriel-Sarah FARTOUKH, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation MÃ©dicale et MÃ©decine Interne, CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Pierre FRAT, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Pierre FRAT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service des Maladies Infectieuses et RÃ©animation MÃ©dicale, CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnaud GACOUIN, MD</last_name>
    </contact>
    <investigator>
      <last_name>Arnaud GACOUIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation Polyvalente, CH de Saint Malo</name>
      <address>
        <city>Saint Malo</city>
        <zip>35403</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>StÃ©phanie CHEVALIER, MD</last_name>
    </contact>
    <investigator>
      <last_name>StÃ©phanie CHEVALIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation</name>
      <address>
        <city>Saint-Brieuc</city>
        <zip>22000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas BARBAROT, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nicolas BARBAROT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation MÃ©dicale, Nouvel HÃ´pital Civil, CHU de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ferhat MEZIANI, MD-PhD</last_name>
    </contact>
    <investigator>
      <last_name>Ferhat MEZIANI, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation MÃ©dicale, HÃ´pital de Hautepierre, CHU de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francis SCHNEIDER, MD-PhD</last_name>
    </contact>
    <investigator>
      <last_name>Francis SCHNEIDER, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>July 31, 2015</study_first_submitted>
  <study_first_submitted_qc>August 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2015</study_first_posted>
  <last_update_submitted>April 13, 2020</last_update_submitted>
  <last_update_submitted_qc>April 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Community-Acquired Pneumonia (CAP)</keyword>
  <keyword>Hydrocortisone</keyword>
  <keyword>Corticosteroids</keyword>
  <keyword>COronaVIrus Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocortisone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 30, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/89/NCT02517489/SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

